. 2022 Feb 25;14(5):1214. doi: 10.3390/cancers14051214

Table 11.

The results of QoL assessment (EORTC QLQ-BR23) in patient groups differing with respect to illness perception and the results of the analysis of variance.

Functional Scales QLQ-BR23	Illness Perception (MEDIS)			ANOVA p
	Positive 0–68 pts.	Neutral 69–94 pts.	Negative 95–140 pts.
	n = 69	n = 68	n = 65
Body image (BRBI)				0.001
M ± SD	56.1 ± 26.8	33.6 ± 26.2	28.3 ± 23.3
Me (Q₁; Q₃)	58 [33; 75]	33 [17; 50]	33 [8; 33]
Min–Max	0–100	0–100	0–92
Sexual functioning (BRSEF)				<0.001
M ± SD	53.8 ± 27.3	32.8 ± 31.3	25.1 ± 25.7
Me (Q₁; Q₃)	50 [33; 67]	33 [0; 50]	33 [0; 33]
Min–Max	0–100	0–100	0–100
Sexual enjoyment (BRSEE)				0.157
M ± SD	43.5 ± 36.5	42.3 ± 36.2	31.4 ± 33.3
Me (Q₁; Q₃)	33 [0; 67]	33 [0; 67]	33 [0; 67]
Min–Max	0–100	0–100	0–100
Future perspective (BRFU)				<0.001
M ± SD	80.0 ± 26.9	76.5 ± 29.4	60.3 ± 31.2
Me (Q₁; Q₃)	100 [67; 100]	100 [33; 100]	67 [33; 100]
Min–Max	0–100	33–100	0–100
Systemic therapy side effects (BRST)				<0.001
M ± SD	21.9 ± 15.9	28.5 ± 18.9	37.9 ± 21.4
Me (Q₁; Q₃)	19 [10; 29]	29 [14; 43]	33 [24; 57]
Min–Max	0–67	0–71	0–100
Breast symptoms (BRBS)				<0.001
M ± SD	17.2 ± 20.9	26.6 ± 25.3	40.0 ± 24.5
Me (Q₁; Q₃)	8 [0; 29]	21 [8; 33]	42 [25; 58]
Min–Max	0–92	0–92	0–92
Arm symptoms (BRAS)				<0.001
M ± SD	24.6 ± 21.7	36.3 ± 22.4	46.0 ± 24.4
Me (Q₁; Q₃)	22 [11; 33]	33 [22; 56]	44 [22; 67]
Min–Max	0–100	0–89	0–89
Upset by hair loss (BRHL)				<0.001
M ± SD	37.1 ± 36.9	50.5 ± 34.3	68.9 ± 27.6
Me (Q₁; Q₃)	33 [0; 67]	33 [33; 67]	67 [67; 100]
Min–Max	0–100	0–100	0–100

M—mean; SD—standard deviation; Me—median; Q₁—lower quartile; Q₃—upper quartile; Min—lowest value; Max—highest value; n—number; values in bold indicate statistical significance (p < 0.05).